Lipocine Inc. Amends Prior Filing on Shareholder Vote Matters

TL;DR

Lipocine filed an amendment to its 8-K, updating a previous report about a shareholder vote. No new financial drama, just paperwork.

AI Summary

Lipocine Inc. filed an amendment (8-K/A) on August 7, 2024, to a previous report originally dated June 5, 2024. This amendment pertains to the submission of matters to a vote of security holders. The filing does not contain new financial figures or specific details about the vote itself, but rather amends the original report.

Why It Matters

This filing indicates an update or correction to a previous report concerning shareholder votes, which could be relevant for investors tracking corporate governance and decision-making processes.

Risk Assessment

Risk Level: low — This is an amendment to a previous filing, primarily for procedural or clarification purposes, and does not introduce new material risks.

Key Players & Entities

• Lipocine Inc. (company) — Registrant
• June 5, 2024 (date) — Date of Earliest Event Reported
• August 7, 2024 (date) — Filing Date
• 8-K/A (document) — Form Type

FAQ

From the Filing

0001493152-24-030545.txt : 20240807 0001493152-24-030545.hdr.sgml : 20240807 20240807160552 ACCESSION NUMBER: 0001493152-24-030545 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240605 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20240807 DATE AS OF CHANGE: 20240807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lipocine Inc. CENTRAL INDEX KEY: 0001535955 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 990370688 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36357 FILM NUMBER: 241183604 BUSINESS ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 BUSINESS PHONE: 801 994 7383 MAIL ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: MARATHON BAR CORP DATE OF NAME CHANGE: 20111130 8-K/A 1 form8-ka.htm true Amendment Number 1 0001535955 0001535955 2024-06-05 2024-06-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K/A   CURRENT REPORT   Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported): June 5, 2024     LIPOCINE INC. (Exact name of registrant as specified in its charter)   Commission File No. 001-36357   Delaware   99-0370688 (State or other jurisdiction of incorporation)   (IRS Employer Identification Number)   675 Arapeen Drive , Suite 202 Salt Lake City , Utah 84108 (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code: (801) 994-7383   Former name or former address, if changed since last report: Not Applicable       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   LPCN   The NASDAQ Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Explanatory Note   This Form 8-K/A (this “Amendment”) is being filed to amend the Form 8-K filed by Lipocine Inc. (the “Company”) on June 5, 2024 (the “Original 8-K”). The Original 8-K was filed with the Securities and Exchange Commission to report the stockholder votes at the Company’s Annual Meeting held on June 5, 2024. The sole purpose of this Amendment is to disclose, in accordance with Item5.07(d) of Form 8-K, the Board of Directors’ decision on the stockholder vote